Jump to ContentJump to Main Navigation

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

4 Issues per year

IMPACT FACTOR 2013: 0.721

Open Access
VolumeIssuePage

Open Access

The Diagnostic Value of Anti-Cyclic Citrullinated Peptide Antibodies (anti-CCP) in Patients with Rheumatoid Arthritis

Ljubinka Damjanovska1 / Violeta Atanasovska1 / Todor Gruev1

Rheumatology Clinic Dr. Dimitar Arsov1

Pediatric Clinic2

Institute of Clinical Biochemistry3

This content is open access.

Citation Information: Journal of Medical Biochemistry. Volume 26, Issue 4, Pages 285–288, ISSN (Online) 1452-8266, ISSN (Print) 1452-8258, DOI: 10.2478/v10011-007-0035-3, December 2007

Publication History

Published Online:
2007-12-10

The Diagnostic Value of Anti-Cyclic Citrullinated Peptide Antibodies (anti-CCP) in Patients with Rheumatoid Arthritis

A cross-sectional study was carried out to analyze the prevalence of anti-CCP antibodies and IgM RF in the sera of 160 randomly selected patients from the Rheumatology Department: 60 with RA, 50 with other rheumatic diseases (non-RA), 50 healthy controls (HC). The mean age of the group was 50.06+/-11.9 years. There were 141 females (88.1%) and 19 males (11.9%). RA patients fulfilled the revised ACR criteria. The mean duration of the disease was 82.4 months. Anti-CCP ELISA kit and IgM RF Latex test were used. The mean anti-CCP values were as follows: RA 60.4+/-57.6, non-RA 2.1+/-3.6, HC 1.3 +/-0.4 U/mL. Respectively, the mean values of IgM RF were: RA 515.8+/-525, non-RA 102+/-294, HC 15+/-57.5. Forty out of 60 (66.6%) RA patients were anti-CCP positive. Forty one out of 60 (68.3%) RA patients were positive for IgM RF. As expected, anti-CCP showed comparable sensitivity (66.8% vs. 68.3%) and higher specificity (98% vs. 87%) than IgM RF, at optimal cut-off values. The presence of either anti-CCP or IgM RF increased the testing sensitivity for the diagnosis of RA to 76.6%. AUC was greater for anti-CCP than for IgM RF (0.92 vs. 0.82).

Dijagnostičko Značenje Anti-Cikličnih Citruliniranih Peptidnih Antitela (anti-CCP) Kod Pacijenata Sa Reumatoidnim Artritisom

Radi utvrđivanja dijagnostičke senzitivnosti i specifičnosti anti-cikličnih citruliniranih peptidnih antitela anti-CCP, kao novog testa za RA urađena je «cross-sectional» studija na Reumatološkoj klinici u Skoplju. Ispitivana grupa sastojala se od 60 bolesnika s reumatoidnim artritisom koji su ispunjavali ACR kriterijume. Kontrolnu grupu 1 sačinjavali su bolesnici sa drugim reumatskim bolestima (50 non-RA), a kontrolnu grupu 2 zdrave osobe (50 ZO). Obuhvaćeni su bolesnici oba pola, 141 žena (88, 1%) i 19 muškaraca (11,9%) prosečne starosti 50,06+/-11,9 godina, dužine trajanja bolesti 82,4 meseca. Upotrebljeni su anti-CCP ELISA kit i IgM RF Latex test. Srednje vrednosti za anti-CCP antitela bile su: RA 60,4+/-57,6, non-RA 2,1+/-3,6, zdravi 1,3 +/-0,4 U/mL. Srednje vrednosti za IgM RF bile su sledeće: RA 515,8+/-525, non-RA102+/-294, zdravi 15 +/-57,5. Četrdeset RA bolesnika (40/60, 66,6%) bili su anti-CCP pozitivni, a 41/60 68,3% bili su IgM RF pozitivni. Kao što smo očekivali, anti-CCP antitela pokazala su skoro identičnu senzitivnost (66,8% vs. 68,3%), ali višu specifičnost (98% vs. 87%) u poređenju sa IgM RF. Pozitivnost za anti-CCP ili IgM RF rezultira povećanjem dijagnostičke senzitivnosti za RA (76,6%). Oblast pod krivom bila je veća kod anti-CCP antitela u odnosu na IgM RF (0,92 vs. 0,82).

Keywords: anti-cyclic citrullinated peptide antibodies; rheumatoid factor; rheumatoid arthritis

Keywords: anti-ciklična citrulinirana peptidna antitela; reumatoidni faktor; reumatoidni artritis

  • Yamada R, Suzuki A, Chang X, Yamamoto K. Citrullinated proteins in RA - Frontiers in biosciences. 2005; 10: 54-64.

  • Finckh A, Liang MH. Anti-cyclic citrullinated peptide antibodies in the diagnosis of Rheumatoid arthritis: Bayes clears the haze. Annals of Internal Medicine 2007; 146: 816-7.

  • Van Venrooij WJ, Zendman A, Nijenhuis S, Vossenaar E, Wiik A, Prujin G. Antibodies to cyclic citrullinated peptides are specific for the diagnosis and prognosis of early RA. Autoimmun Review 2006; 6 (1): 37-41. [CrossRef]

  • Chaiamnuay S, Bridges SL. The role of B cells and autoantibodies in rheumatoid arthritis. Pathophysiology 2005; 12: 203-16. [CrossRef] [PubMed]

  • Nijenhuis S, Zendman A, Vossenaar ER, Pruijn G, Van Venrooij W. Autoantibodies to citrullinated proteins in RA: Clinical performance and biological aspects of an RA-specific marker. Clinica Chimica Acta 2004; 350: 17-34.

  • Riedman JP, Munoz S, Kavanaugh A. The use of second generation anti-CCP antibodies (Anti-CCP2) testing in RA - A systematic review. Clin Exp Rheumatol 2005; 23: S69-S76.

  • Schellekens G, Visser H, De Jong B, Van den Hoogen F, Hazes J, Breedveld F, Van Venrooij W. The diagnostic properties of Rheumatoid arthritis antibodies recognizing cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-63. [CrossRef]

  • Avouac J, Gossec L, Dougados M. Diagnostic and predictive values of anti-cyclic citrullinated protein antibodies in Rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65: 845-51.

  • Mimori T. Clinical significance of Anti-CCP antibodies in RA. Internal Med 2005; 44: 1122-6. [CrossRef]

  • Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: Diagnostic accuracy of anti-CCP antibody and RF for Rheumatoid arthritis. Ann Int Med 2007; 146: 797-808.

  • Nell VK, Machold KP, Stamm TA, Eberl G, Heincl H, Uffmann M, Smolen JS, Steiner G. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1731-6. [CrossRef] [PubMed]

Comments (0)

Please log in or register to comment.